Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial

Ann Palliat Med. 2020 Mar;9(2):504-509. doi: 10.21037/apm.2020.02.03. Epub 2020 Mar 17.

Authors

Maeve A Hennessy¹, Patrick G Morris²

Affiliations

¹ Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
² Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland; Royal College of Surgeons in Ireland, Dublin, Ireland. patrickmorris@beaumont.ie.

PMID: 32233616
DOI: 10.21037/apm.2020.02.03

No abstract available

Publication types

Editorial

MeSH terms

Ado-Trastuzumab Emtansine / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism*
Breast Neoplasms / mortality
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
Receptor, ErbB-2 / metabolism*

Substances

Antibodies, Monoclonal, Humanized
ERBB2 protein, human
Receptor, ErbB-2
Ado-Trastuzumab Emtansine